Advertisement

Cost of colorectal cancer by treatment type from different health economic perspectives: A systematic review

      Abstract

      Advancements in colorectal cancer treatment have substantially improved overall survival. However, the cost of treating colorectal cancer places a significant economic burden on populations and healthcare systems. It is accepted that costs and what a health system charges may differ. This study aims to understand the expenditure on colorectal cancer globally. Specifically, this paper systematically reviews the literature to estimate the direct costs of each component in treating colorectal cancer, including primary care, diagnostics, surgery, chemotherapy, radiotherapy, and follow-up. MEDLINE, EMBASE, Web of Science, Evidence-Based Medicine Reviews: National Health Service Economic Evaluation Database Guide, Econlit and grey literature from the January 1, 2000 to the February 1, 2020. The methodological quality of the included studies was assessed using the Evers’ Consensus on Health Economic Criteria checklist. In total, 39,489 records were retrieved, and after appropriate culling of non-relevant articles, 15 studies were included. Costs for treating colorectal cancer varied due to heterogeneity between different studies despite comparing similar clinical settings and study perspectives. Studies that presented an average cost per patient demonstrated that surgical costs ranged from $1,149 to $34,606, chemotherapy ranged from $1,883 to $18,021 and radiotherapy ranged from $2,037 to $5,347 in 2018 USD. Identifying these costs can impact health care budgets and guide policymakers in making informed decisions for the future.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • Laversanne M.
        • Soerjomataram I.
        • Jemal A.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin, 2021 (n/a(n/a))
      1. Health AIo, Welfare. Cancer in Australia 2019. Canberra: AIHW; 2019.

      2. Society AC. Colorectal Cancer Risk Factors 2020 [Available from: https://www.cancer.org/cancer/colon-rectal-cancer/causes-risks-prevention/risk-factors.html.

        • Brenner H.
        • Kloor M.
        • Pox C.P.
        Colorectal cancer.
        Lancet. 2014; 383: 1490-1502
        • Ciombor K.K.
        • Bekaii-Saab T.
        A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer.
        Oncol. 2018; 23: 25-34
        • Zadlo J.
        Cost-effectiveness of new and emerging treatment options for the treatment of metastatic colorectal cancer.
        Am J Manag Care. 2018; 24 (S118-s24)
        • Sekiguchi M.
        • Igarashi A.
        • Sakamoto T.
        • Saito Y.
        • Esaki M.
        • Matsuda T.
        Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
        J Gastroenterol Hepatol. 2020; 35: 1555-1561
        • Senore C.
        • Hassan C.
        • Regge D.
        • Pagano E.
        • Iussich G.
        • Correale L.
        • et al.
        Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
        J Med Screen. 2019; 26: 76-83
        • Carvalho A.C.
        • Leal F.
        • Sasse A.D.
        Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
        PLoS One. 2017; 12e0175409
        • Bramer W.M.
        • Giustini D.
        • de Jonge G.B.
        • Holland L.
        • Bekhuis T.
        De-duplication of database search results for systematic reviews in EndNote.
        J Med Libr Assoc. 2016; 104: 240-243
        • Fireman B.H.
        • Quesenberry C.P.
        • Somkin C.P.
        • Jacobson A.S.
        • Baer D.
        • West D.
        • et al.
        Cost of care for cancer in a health maintenance organization.
        Health Care Financ Rev. 1997; 18: 51-76
        • Evers S.
        • Goossens M.
        • de Vet H.
        • van Tulder M.
        • Ament A.
        Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria.
        Int J Technol Assess Health Care. 2005; 21: 240-245
        • Higgins J.P.
        • Thomas J.
        • Chandler J.
        • Cumpston M.
        • Li T.
        • Page M.J.
        • et al.
        Cochrane handbook for systematic reviews of interventions.
        John Wiley & Sons, 2019
        • Corral J.
        • Borras J.M.
        • Chiarello P.
        • Garcia-Alzorriz E.
        • Macia F.
        • Reig A.
        • et al.
        Estimation of hospital costs of colorectal cancer in Catalonia (Spain).
        Gac Sanit. 2015; 29: 437-444
        • Song X.
        • Zhao Z.
        • Barber B.
        • Gregory C.
        • Cao Z.
        • Gao S.
        Cost of illness in patients with metastatic colorectal cancer.
        J Med Econ. 2011; 14: 1-9
        • Chang S.
        • Long S.R.
        • Kutikova L.
        • Bowman L.
        • Finley D.
        • Crown W.H.
        • et al.
        Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
        J Clin Oncol. 2004; 22: 3524-3530
        • Warren J.L.
        • Yabroff K.R.
        • Meekins A.
        • Topor M.
        • Lamont E.B.
        • Brown M.L.
        Evaluation of trends in the cost of initial cancer treatment.
        J Natl Cancer Inst. 2008; 100: 888-897
        • Huang H.Y.
        • Shi J.F.
        • Guo L.W.
        • Bai Y.N.
        • Liao X.Z.
        • Liu G.X.
        • et al.
        Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey.
        Chin Times. 2017; 36: 41
        • Shi J.F.
        • Liu G.X.
        • Wang H.
        • Mao A.
        • Liu C.C.
        • Guo L.W.
        • et al.
        Medical expenditures for colorectal cancer diagnosis and treatment: a 10-year high-level-hospital-based multicenter retrospective survey in China, 2002-2011.
        Chin J Cancer Res. 2019; 31: 825-+
        • Xu J.F.
        • Nicholas S.
        • Wang J.
        • Yang Y.X.
        A retrospective analysis of hospital treatment expenditures among young and middle age patients with cancer, 2013-2017 under health reform.
        Int J Health Plann Manag. 2020; : 10
      3. Le NQ, Vo TQ, Doan TD. Analyzing the variation in treatment costs for colorectal cancer (CRC): a retrospective study to assess an underlying threat among the Vietnamese. Jpma. 2019;J Pakistan Med Assoc. Suppl. 69 2)(6):S34-S40.

        • Li T.Y.
        • Hsieh J.S.
        • Lee K.T.
        • Hou M.F.
        • Wu C.L.
        • Kao H.Y.
        • et al.
        Cost trend analysis of initial cancer treatment in Taiwan.
        PLoS One. 2014; 9 ((no pagination)e108432
        • Shin J.Y.
        • Kim S.Y.
        • Lee K.S.
        • Lee S.I.
        • Ko Y.
        • Choi Y.S.
        • et al.
        Costs during the first five years following cancer diagnosis in Korea.
        Asian Pac J Cancer Prev APJCP. 2012; 13: 3767-3772
        • Alefan Q.
        • Malhees R.
        • Mhaidat N.
        Direct medical cost associated with colorectal cancer in north of Jordan.
        Curr Probl Cancer. 2017; 41: 371-381
        • Vahdatimanesh Z.
        • Zendehdel K.
        • Kbari Sari A.A.
        • Farhan F.
        • Nahvijou A.
        • Delavari A.
        • et al.
        Economic burden of colorectal cancer in Iran in 2012.
        Med J Islam Repub Iran. 2017; 31: 115
        • Sermsri N.
        • Boonpipattanapong T.
        • Prechawittayakul P.
        • Sangkhathat S.
        Influence of payer source on treatment and outcomes in colorectal cancer patients in a university hospital in Thailand.
        . 2014; 1: 9015-9019
        • Vekic B.
        • Dragojevic-Simic V.
        • Jakovljevic M.
        • Pilipovic F.
        • Simic R.
        • Zivic R.
        • et al.
        Medical cost of colorectal cancer services in Serbia between 2014 and 2017: national data report.
        Front Pharmacol. 2019; 10 (MAY) (no pagination
        • Herman K.J.
        • Komorowski A.L.
        • Wysocki W.M.
        • Tabor J.
        • Herman R.M.
        • Sliwczynski A.
        Variation in treatment modalities, costs and outcomes of rectal cancer patients in Poland.
        Wspólczesna Onkol. 2015; 19: 400-409
        • Goldstein D.A.
        • Clark J.
        • Tu Y.
        • Zhang J.
        • Fang F.
        • Goldstein R.
        • et al.
        A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.
        Oncotarget. 2017; 8: 71548-71555
      4. Organisation for Economic Co-operation and Development. Healthcare expenditure and financing 2021 [Available from: https://stats.oecd.org/Index.aspx?ThemeTreeId=9#.

        • Hofmarcher T.
        • Lindgren P.
        • Wilking N.
        • Jönsson B.
        The cost of cancer in Europe 2018.
        Eur J Cancer. 2020; 129: 41-49